Suppr超能文献

氯化钙去凝人血小板裂解物可促进间充质基质细胞的扩增,并有助于制备具有免疫调节活性的细胞外囊泡产品。

Calcium chloride declotted human platelet lysate promotes the expansion of mesenchymal stromal cells and allows manufacturing of immunomodulatory active extracellular vesicle products.

作者信息

Mouloud Yanis, Staubach Simon, Stambouli Oumaima, Mokhtari Shakiba, Kutzner Tanja J, Zwanziger Denise, Hemeda Hatim, Giebel Bernd

机构信息

Institute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Institute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; Sartorius Stedim Biotech GmbH, Göttingen, Germany.

出版信息

Cytotherapy. 2024 Sep;26(9):988-998. doi: 10.1016/j.jcyt.2024.04.069. Epub 2024 Apr 27.

Abstract

BACKGROUND

Mesenchymal stromal cells (MSCs) exert immunomodulatory effects, primarily through released extracellular vesicles (EVs). For the clinical-grade manufacturing of MSC-EV products culture conditions need to support MSC expansion and allow the manufacturing of potent MSC-EV products. Traditionally, MSCs are expanded in fetal bovine serum-supplemented media. However, according to good manufacturing practice (GMP) guidelines the use of animal sera should be avoided. To this end, human platelet lysate (hPL) has been qualified as an animal serum replacement. Although hPL outcompetes animal sera in promoting MSC expansion, hPL typically contains components of the coagulation system that need to be inhibited or removed to avoid coagulation reactions in the cell culture. Commonly, heparin is utilized as an anticoagulant; however, higher concentrations of heparin can negatively impact MSC viability, and conventional concentrations alone do not sufficiently prevent clot formation in prepared media.

METHODS

To circumvent unwanted coagulation processes, this study compared various clotting prevention strategies, including different anticoagulants and calcium chloride (CaCl)-mediated declotting methods, which in combination with heparin addition was found effective. We evaluated the influence of the differently treated hPLs on the proliferation and phenotype of primary bone marrow-derived MSCs and identified the CaCl-mediated declotting method as the most effective option. To determine whether CaCl declotted hPL allows the manufacturing of immunomodulatory MSC-EV products, EVs were prepared from conditioned media of MSCs expanded with either conventional or CaCl declotted hPL. In addition to metric analyses, the immunomodulatory potential of resulting MSC-EV products was assessed in a recently established multi-donor mixed lymphocyte reaction assay.

RESULTS AND CONCLUSIONS

Our findings conclusively show that CaCl-declotted hPLs support the production of immunomodulatory-active MSC-EV products.

摘要

背景

间充质基质细胞(MSCs)发挥免疫调节作用,主要是通过释放细胞外囊泡(EVs)。对于临床级别的MSC-EV产品制造,培养条件需要支持MSCs的扩增,并允许制造有效的MSC-EV产品。传统上,MSCs在补充有胎牛血清的培养基中扩增。然而,根据良好生产规范(GMP)指南,应避免使用动物血清。为此,人血小板裂解物(hPL)已被认定为动物血清替代品。尽管hPL在促进MSCs扩增方面优于动物血清,但hPL通常含有凝血系统的成分,需要抑制或去除这些成分以避免细胞培养中的凝血反应。通常,肝素被用作抗凝剂;然而,较高浓度的肝素会对MSCs的活力产生负面影响,仅使用常规浓度的肝素不足以防止制备好的培养基中形成凝块。

方法

为了规避不必要的凝血过程,本研究比较了各种预防凝血的策略,包括不同的抗凝剂和氯化钙(CaCl)介导的解凝方法,发现这些方法与添加肝素相结合是有效的。我们评估了不同处理的hPLs对原代骨髓来源的MSCs增殖和表型的影响,并确定CaCl介导的解凝方法是最有效的选择。为了确定CaCl解凝的hPL是否允许制造免疫调节性的MSC-EV产品,从用常规hPL或CaCl解凝的hPL扩增的MSCs的条件培养基中制备EVs。除了进行指标分析外,还在最近建立的多供体混合淋巴细胞反应试验中评估了所得MSC-EV产品的免疫调节潜力。

结果与结论

我们的研究结果确凿地表明,CaCl解凝的hPLs支持生产具有免疫调节活性的MSC-EV产品。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验